Stemline Therapeutics, Inc.
- Country
- 🇺🇸United States
- Ownership
- Public, Subsidiary
- Established
- 2003-08-01
- Employees
- 100
- Market Cap
- -
- Website
- http://www.stemline.com
A First-in-Human Study of MEN2312 in Adults With Advanced Breast Cancer
- First Posted Date
- 2024-10-15
- Last Posted Date
- 2025-05-07
- Lead Sponsor
- Stemline Therapeutics, Inc.
- Target Recruit Count
- 124
- Registration Number
- NCT06638307
- Locations
- 🇺🇸
Highlands Oncology Group, Springdale, Arkansas, United States
🇺🇸UC San Diego Moores Cancer Center, La Jolla, California, United States
🇺🇸UCLA Jonsson Comprehensive Cancer Center, Los Angeles, California, United States
A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of Recurrence
- Conditions
- Breast Cancer
- Interventions
- First Posted Date
- 2024-07-09
- Last Posted Date
- 2025-05-21
- Lead Sponsor
- Stemline Therapeutics, Inc.
- Target Recruit Count
- 4220
- Registration Number
- NCT06492616
- Locations
- 🇪🇸
Hospital Beata Maria Ana, Madrid, Spain
🇺🇸Southern Cancer Center, PC, Daphne, Alabama, United States
🇺🇸Banner MD Anderson Cancer Center, Gilbert, Arizona, United States
A Study of Tagraxofusp in Combination With Venetoclax and Azacitidine in Adults With Untreated CD123+ Acute Myeloid Leukemia Who Cannot Undergo Intensive Chemotherapy
- Conditions
- Acute Myeloid Leukemia
- Interventions
- First Posted Date
- 2024-06-13
- Last Posted Date
- 2025-04-02
- Lead Sponsor
- Stemline Therapeutics, Inc.
- Target Recruit Count
- 76
- Registration Number
- NCT06456463
- Locations
- 🇺🇸
University of California, Los Angeles, Los Angeles, California, United States
🇺🇸University of Miami Sylvester Comprehensive Cancer Center, Miami, Florida, United States
🇺🇸AdventHealth Cancer Institute, Orlando, Florida, United States
A PK Study Testing Single Oral Dose of Elacestrant in Subjects With Normal or Severely Impaired Hepatic Function
- First Posted Date
- 2023-11-13
- Last Posted Date
- 2024-11-19
- Lead Sponsor
- Stemline Therapeutics, Inc.
- Target Recruit Count
- 16
- Registration Number
- NCT06126575
- Locations
- 🇺🇸
Inland Empire Clinical Trials, LLC, Yucaipa, California, United States
🇺🇸Floridian Clinical Research, Miami, Florida, United States
🇺🇸American Research Corp, San Antonio, Texas, United States
ELACESTRANT in Women and Men With CDK4/6 Inhibitor-Naive Estrogen Receptor Positive, HER-2 Negative Metastatic Breast Cancer Study
- First Posted Date
- 2022-10-27
- Last Posted Date
- 2025-03-26
- Lead Sponsor
- Stemline Therapeutics, Inc.
- Target Recruit Count
- 80
- Registration Number
- NCT05596409
- Locations
- 🇬🇪
Todua Clinic, Tbilisi, Georgia
🇺🇸Northwestern University, Northwestern Feinberg School of Medicine Prentice Women's Hospital, Chicago, Illinois, United States
🇲🇽I CAN Oncology Center, Centro Medico AVE, Monterrey, Nuevo Leon, Mexico
Open-Label Umbrella Study To Evaluate Safety And Efficacy Of Elacestrant In Various Combination In Patients With Metastatic Breast Cancer
- Conditions
- Breast CancerMetastatic Breast Cancer
- Interventions
- First Posted Date
- 2022-10-03
- Last Posted Date
- 2025-05-02
- Lead Sponsor
- Stemline Therapeutics, Inc.
- Target Recruit Count
- 400
- Registration Number
- NCT05563220
- Locations
- 🇺🇸
Dothan Hematology and Oncology, Dothan, Alabama, United States
🇺🇸Mayo Clinic - Arizona, Phoenix, Arizona, United States
🇺🇸Highlands Oncology Group, Springdale, Arkansas, United States
Study of Abemaciclib and Elacestrant in Patients With Brain Metastasis Due to ER+/HER-2- Breast Cancer
- Conditions
- Neoplasms by SiteNeoplasmsBrain DiseasesBrain NeoplasmsCentral Nervous System NeoplasmsCentral Nervous System DiseasesBreast NeoplasmsBreast Diseases
- Interventions
- First Posted Date
- 2022-05-23
- Last Posted Date
- 2025-05-07
- Lead Sponsor
- Stemline Therapeutics, Inc.
- Target Recruit Count
- 68
- Registration Number
- NCT05386108
- Locations
- 🇺🇸
Providence Medical Foundation, Fullerton, California, United States
🇺🇸California Research Institute, Los Angeles, California, United States
🇺🇸Carle Cancer Center, Urbana, Illinois, United States
Study of the PI3K Inhibitor SL-901 in Patients With Advanced Solid Tumors
- First Posted Date
- 2022-05-19
- Last Posted Date
- 2025-01-09
- Lead Sponsor
- Stemline Therapeutics, Inc.
- Target Recruit Count
- 20
- Registration Number
- NCT05382936
- Locations
- 🇬🇧
Royal Marsden Hospital, Sutton, Surrey, United Kingdom
🇬🇧Christie Hospital, Manchester, United Kingdom
Phase 3 Trial of Elacestrant vs. Standard of Care for the Treatment of Patients With ER+/HER2- Advanced Breast Cancer
- First Posted Date
- 2018-12-19
- Last Posted Date
- 2024-10-30
- Lead Sponsor
- Stemline Therapeutics, Inc.
- Target Recruit Count
- 478
- Registration Number
- NCT03778931
- Locations
- 🇺🇸
Dayton Oncology & Hematology, Kettering, Ohio, United States
🇺🇸Keck Medical Center of USC, Los Angeles, California, United States
🇺🇸UCLA Hematology/Oncology, Los Angeles, California, United States
Phase 1, First-in-Human Study of RAD140 in Postmenopausal Women With Breast Cancer
- Conditions
- Hormone Receptor Positive Malignant Neoplasm of Breast
- Interventions
- First Posted Date
- 2017-03-23
- Last Posted Date
- 2022-08-18
- Lead Sponsor
- Stemline Therapeutics, Inc.
- Target Recruit Count
- 20
- Registration Number
- NCT03088527
- Locations
- 🇺🇸
Cancer Center Protocol Office, Boston, Massachusetts, United States
🇺🇸Barbara Ann Karmanos Cancer Center, Detroit, Michigan, United States
🇺🇸Washington University School of Medicine, Saint Louis, Missouri, United States